NR1D2 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Bektashism (Turkish: Bektaşîlik, Albanian: Bektashi) is a Sufi order of Islam that evolved in 13th-century western Anatolia and became widespread in the Ottoman Empire. It is named after the walī (saint) Haji Bektash Veli, with adherents called Bektashis. Origins of Haji Bektash's teachings can be traced back to the scholar Ahmad Yasawi of Turkestan. The highest title in Bektashi chain of succession is Dedebaba, followed by Halifebaba and Baba. The Bektashi Order of Tirana is currently led by Baba Mondi, recognized as the eighth Dedebaba, whose seat is at the order’s headquarters in Tirana, Albania. However, the Bektashi Order of Tirana is not recognized by Turkish Bektashis, specifying that Bektashi principles require Dedebaba to be in Anatolia, and the Albanian chain of succession never had Dedebabate. Bektashis believe in the ismah of the prophets and messengers and the Fourteen Infallibles: Muhammad, his daughter Fatima, and the Twelve Imams. In contrast to many Twelver Shia, Bektashis respect all of the Companions of Muhammad, including Abu Bakr, Umar, Uthman, Talha, Zubayr and Mu'awiya, with Ali considered the greatest of the Companions.
On 5 October, the 2025 Syrian parliamentary election was held in the temporary electoral system as an indirect vote, where only around 6,000 selected Syrians were eligible. 140 members were due to be elected by the electoral college, although only 119 were elected on election day due to postponement in select areas from security concerns. On 1 July, President Ahmed al-Sharaa appointed the remaining 70 additional members. The People's Assembly building underwent renovation by late 2025, the first since 2009, delaying the appointment of the 70 seats appointed by the president of Syria. While in at a meeting in the Royal Institute of International Affairs on 31 March 2026, al-Sharaa announced that the People's Assembly will be seated within the month. The first post-Assad People's Assembly was subsequently finalized in early July 2026, with its inaugural session originally scheduled for 6 July; however, a day before the scheduled date, the Higher Committee for People's Assembly Elections had announced that the inaugural session will be postponed to a later date. The inaugural session of the People's Assembly was held on 12 July 2026. At its second session, the Assembly passed a resolution setting up much of its internal procedures and structure; among the articles were provisions that the parliament cannot be dissolved by the President, must ratify international agreements and constitutional amendments, will broadcast its sessions publicly, and retains parliamentary immunity for its members only for when conducting parliamentary affairs.
Vitamin K: CID 5280483 from PubChem Vitamin K1 (phylloquinone, phytomenadione): CID 5284607 from PubChem Vitamin K2 (menaquinone 6): CID 5283547 from PubChem Vitamin K3 (menadione): CID 4055 from PubChem
Sources: en.wikipedia.org
== Disease cycle == P. expansum infects a fruit via wounds through which the conidia are able to enter. Usually, puncturing, bruising, and limb rubs occur during harvesting, packaging, and processing of the fruit, all of which provide sites through which spores can enter the fruit. Conidia can be found in soil, decaying debris, and tree bark, and can survive cold temperatures. Conidia may be isolated from the air of the orchard and packaging house, on the walls of the packaging houses, and from the water and fungicide solution into which harvested fruits are dunked before packaging or storage. Exposure to conidia at any step of growth, harvesting, processing, shipping, and storage can lead to inoculation and disease. Conidia that have gained access via a wound can germinate to form a germ tube. This germ tube will continue to grow as hyphae, which colonize the fruit, killing fruit cells in an expanding infection. If the fungus has colonized the fruit with mycelium, the formation of conidiophores occurs on the surface or subsurface of the hyphae. The conidiophores are mostly smooth-walled terverticillate penicilli. A terverticillate pencilii has multiple branch points below the phialides, the cells that the conidia are attached to. However, at times, the penicilli may be rough or biverticillate (only two levels of branching). The phialides are packed close together with nearly a cylindrical shape. The conidia are dry, smooth, elliptical, and "dull-green" in color and are often disseminated by wind currents. Sexual reproduction has not been observed in nature for P. expansum.
== Prognosis == Duchenne muscular dystrophy is a rare progressive disease that eventually affects all voluntary muscles and involves the heart and breathing muscles in later stages. Life expectancy is estimated to be around 25–26, but this varies. People born with Duchenne muscular dystrophy after 1990 have a median life expectancy of approximately 28–30. With excellent medical care, affected men often live into their 30s. The oldest surviving person in the world with the disease is 64 years old. The most common direct cause of death in people with Duchenne muscular dystrophy is respiratory failure. Complications from treatment, such as mechanical ventilation and tracheotomy procedures, are also a concern. The next leading cause of death is cardiac-related conditions such as heart failure brought on by dilated cardiomyopathy. With respiratory assistance, the median survival age can reach up to 40. In rare cases, people with Duchenne muscular dystrophy have been seen to survive into their forties or early fifties, with proper positioning in wheelchairs and beds, and the use of ventilator support (via tracheostomy or mouthpiece), airway clearance, and heart medications. Early planning of the required supports for later-life care has shown greater longevity for people with Duchenne muscular dystrophy. Curiously, in the mdx mouse model of Duchenne muscular dystrophy, the lack of dystrophin is associated with increased calcium levels and skeletal muscle myonecrosis. The intrinsic laryngeal muscles (ILMs) are protected and do not undergo myonecrosis.
1993/931) Friendly Societies Act 1992 (Transitional and Consequential Provisions and Savings) Regulations 1993 (S.I. 1993/932) Finance Act 1991, section 58, (Commencement No. 3) Regulations 1993 (S.I. 1993/933) Legal Aid in Criminal and Care Proceedings (Costs) (Amendment) Regulations 1993 (S.I. 1993/934) Housing Benefit and Community Charge Benefit (Subsidy) (No. 2) Order 1993 (S.I. 1993/935) Certification Officer (Amendment of Fees) Regulations 1993 (S.I. 1993/936) Further Education (Exclusion of Land from Transfer) (No. 2) Order 1993 (S.I. 1993/937) Land Registry Trading Fund Order 1993 (S.I. 1993/938) Land Registration (Determination of Costs) Order 1993 (S.I. 1993/939) Local Government Administration (Matters Subject to Investigation) Order 1993 (S.I. 1993/940) Local Elections (Variation of Limits of Candidates' Election Expenses) (Northern Ireland) Order 1993 (S.I. 1993/941) Copyright (Application to Other Countries) Order 1993 (S.I. 1993/942) Performances (Reciprocal Protection) (Convention Countries) Order 1993 (S.I. 1993/943) European Communities (Definition of Treaties) (International Railway Tariffs Agreements) Order 1993 (S.I. 1993/944) Insurance Companies (Accounts and Statements) (Amendment) Regulations 1993 (S.I. 1993/946) Patents (Supplementary Protection Certificate for Medicinal Products) (Amendment) Rules 1993 (S.I. 1993/947) Chessington Computer Centre Trading Fund Order 1993 (S.I. 1993/948) Income Tax (Interest Relief) (Qualifying Lenders) Order 1993 (S.I. 1993/949) Capital Gains Tax (Gilt-edged Securities) Order 1993 (S.I.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.